Patient Case 2: Development of ICANS on a BCMA-Targeted Bispecific Antibody

Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.

Related Videos
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Experts on multiple myeloma
Expert on prostate cancer
Experts on multiple myeloma
MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma
Related Content